Bristol Myers Squibb Company $BMY Shares Sold by Burney Co.

Burney Co. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 12.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,792 shares of the biopharmaceutical company’s stock after selling 1,576 shares during the quarter. Burney Co.’s holdings in Bristol Myers Squibb were worth $500,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in shares of Bristol Myers Squibb by 297.0% during the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company’s stock valued at $1,447,198,000 after acquiring an additional 17,750,938 shares in the last quarter. GQG Partners LLC lifted its holdings in shares of Bristol Myers Squibb by 22,647.6% during the 1st quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company’s stock valued at $733,310,000 after acquiring an additional 11,970,598 shares in the last quarter. Nuveen LLC acquired a new position in shares of Bristol Myers Squibb during the 1st quarter valued at $624,369,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at $98,898,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Bristol Myers Squibb by 17.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,051,319 shares of the biopharmaceutical company’s stock valued at $856,990,000 after acquiring an additional 2,117,249 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY opened at $46.50 on Thursday. The company has a 50-day moving average of $45.26 and a 200-day moving average of $46.73. The company has a market capitalization of $94.66 billion, a P/E ratio of 18.75, a PEG ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.3%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.07% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BMY has been the topic of several recent research reports. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Finally, Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fifteen have issued a Hold rating to the company. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $57.23.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.